Status:
UNKNOWN
Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)
Lead Sponsor:
Kagoshima University
Conditions:
Hypertension
Obesity
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The purpose of this study is to consider the following points in patients with hypertension who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard treatment. * ...
Detailed Description
The primary endpoints are: * blood pressure control * Adiponectin and plasma type1 plasminogen active inhibitor The secondary endpoints are * HOMA-IR * HbA1c * TNF-α * IL-6 * Plasma B-type natriure...
Eligibility Criteria
Inclusion
- Out patients with hypertension male and female
- Systolic blood pressure (SBP)≧140mmHg and/or diastolic blood pressure (DBP)≧90 mmHg
- Waist Surrounding diameter male≧85cm female≧90cm
- Patient who is treating either high triglyceride,low HDL,or diabetes mellitus
- Patient who is untreatment high triglyceride blood syndrome and low HDL blood syndrome,diabetes mellitus is triglceride≧150mg/dl and/or HDL cholesterol \< 40 mg/dl or fasting blood glucose ≧110 mg/dl
- Untreated patients with hypertension,or patients is treated with antihypertensive agents except for ACE-I and ARB
Exclusion
- Patient who is using ACE-I and ARB
- Serum creatinine ≧ 3 mg/dl
- Liver impairment
- History of allergy to valsartan
- Pregnant women
- Judgment by the physician that participation was unwise on the basis of patient characteristics and drug safety
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT00790946
Start Date
June 1 2006
End Date
December 1 2009
Last Update
June 3 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chuwa Tei,MD,FACC,FAHA
Kagoshima, Kagoshima-ken, Japan, 890-8520